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Summary Human anti-murine antibody (HAMA) response is a serious problem in the repeated infusion of
murine monoclonal antibodies (MoAbs). HAMA positive sera were obtained from seven patients with
colorectal cancer, pancreas cancer, malignant melanoma or myocardial infarction who had previously received
radiolabelled MoAbs. The nature of HAMA was analysed using size exclusion high performance liquid
chromatography (HPLC) after incubating with radiolabelled MoAbs including IgG, Fab or human/mouse
chimeric Abs. Immune complexes composed of HAMA and MoAbs were formed. The percentage of
radioactivity with a high molecular weight was related to HAMA levels determined by enzyme linked
immunosorbent assay. Most radioactivity present in immune complex shifted to the antibody fraction after the
addition of normal murine serum. All of seven sera were reactive with all four murine IgGs and this suggests
that HAMA in these patients recognised the constant region of MoAbs. In one patient, HAMA was
considered to recognise the variable region and to be anti-idiotypic. There was no significant binding with
human/mouse chimeric Abs in any HAMA positive serum, although five out of seven patients were reactive
with murine MoAb Fab, indicating that HAMA was composed of Abs responsive to the CH1 or CL region of
murine IgG. These results suggest that (1) HAMA was composed of Ab responsive to Fc portion and/or CHI
or CL region of murine IgG, and (2) human/mouse chimeric Abs look promising in the repeated infusion of
MoAb in HAMA positive patients.
Most monoclonal antibodies (MoAbs) used in the diagnosis
and therapy of cancer or acute myocardial infarction are
derived from mice, and the development of human anti-
murine monoclonal antibodies (HAMA) in patients who
received murine MoAbs intravenously continues to limit
severely their repeated application. Circulating HAMA may
form high molecular weight complexes with the injected
MoAbs, resulting in rapid blood clearance and reduced
tumour targeting and may cause serious sickness (Shroff et
al., 1985; Shawler et al., 1985; Courtenay-Luck et al., 1986;
Sakahara et al., 1989). However the development of HAMA
differs among patients and the form of the MoAb; that is,
whether it is whole IgG, Fab or F(ab')2 fragments (Brown et
al., 1988).
Recently human/mouse chimeric MoAbs have been effic-
iently engineered by ligating the heavy chain enhancer ele-
ment to chimeric light and heavy chain genes (Morrison et
al., 1984; Nishimura et al., 1987). The antigenicity of these
human/mouse chimeric Abs are expected to be reduced when
intravenously infused.
We investigated the properties of circulating HAMA in the
sera of patients who were administered whole IgG, F(ab')2 or
Fab fragment or murine MoAbs, using size exclusion high
performance liquid chromatography (HPLC) analysis. We
present the heterogeneous nature of HAMA and the poten-
tial of human/mouse anti-tumour chimeric monoclonal anti-
bodies in these HAMA positive patients.
Materials and methods
Monoclonal antibodies
The MoAb designated ZCE-025 is a murine IgGI recognising
CEA and was provided by Hybritech Inc. (San Diego, CA)
through Teijin Ltd. (Tokyo, Japan) in a purified DTPA-
coupled form. MoAb 96.5 is a murine IgG2a recognising
melanoma cell surface antigen p97. NL-1 is a murine IgG2a
antibody directed against common acute lymphocytic leu-
kaemia antigen (CALLA) identical with CDI0 (Letarte et al.,
1988; Monod et al., 1989). Human/mouse chimeric NL-1
(cNL-1) antibody was obtained by ligating the human heavy-
chain enhancer element to the chimeric heavy- and light-
chain genes as previously reported (Nishimura et al., 1987;
Saga et al., 1990). The Fab fragment of RIIDIO, an anti-
myosin antibody (Khaw et al., 1984; Khaw et al., 1987), was
provided by Centocor (Malvern, PA) through Daiichi Radio-
isotope Laboratories Ltd. (Tokyo, Japan) in an "'In-labelled
form. SF-25 antibody, generated by fusing myeloma cells and
spleen cells of mice immunised with human hepatocellular
carcinoma cells, is an IgG, antibody reactive with the 125
kilodalton antigen on the cell surface of some hepatocellular
carcinoma and colon cancers (Takahashi et al., 1988). This
antibody and its human/mouse chimeric counterpart were
provided by Centocor through Toray Industries, Inc. (Tokyo,
Japan).
Radiolabelling ofmonoclonal antibodies
MoAbs 96.5, NL-1, chimeric NL-1, SF-25 and chimeric SF-
25 were radioiodinated by the chloramine-T method (Hunter
et al., 1962; Greenwood et al., 1963). In brief, antibodies
(40fLg) in 0.3 M phosphate-buffer (PB), pH 7.5, and 1251 for
protein labelling (Amersham International plc, Buckingham-
shire, UK) were mixed with 2.5 ytg of chloramine-T (Nakarai
Chemicals, Kyoto, Japan) dissolved in 0.3 M PB. After 5 min
of reaction, '251I-labelled MoAb was separated from free 1251I
by Sephadex G-25 gel chromatography. The labelling effic-
iency was from 60 to 80%.
DTPA-conjugated ZCE-025 was labelled with "'In after a
30 min incubation with "'In-chloride (Nihon Mediphysics,
Takarazuka, Japan). The labelling efficiency was more than
90% without further purification (Sakahara et al., 1985). Correspondence: M. Hosono, Department of Nuclear Medicine,
Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku,
Kyoto 606, Japan.
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Human anti-murine antibody (HAMA) determination by
enzyme linked immunosorbent assay (ELISA)
The Fab fragment of anti-myosin Ab or a mixture of murine
monoclonal antibodies (whole IgG) was immobilised in 96-
well polystyrene plates (Costar, MA, USA) by coating a well
with 5 tLg of Ab in glycine buffer pH 8.5 containing 5 mM
EDTA at 4°C for 20 h. The plates were washed with 0.15 M
phosphate buffered saline (PBS) containing 0.05% Tween
(PBS-Tween), incubated with PBS containing 0.5% bovine
serum albumin (BSA) at 37°C for an hour, and again washed
with PBS-Tween. Serially diluted serum samples were added
and incubated at 37°C for 1 h. After washing the plates with
PBS-Tween, 50 LIl of goat anti-human IgG coupled with
horseradish peroxidase was added to each well and incubated
at 37°C for 1 h. The plates were washed with PBS-Tween and
200 tLI of o-phenylenediamine in citrate buffer was added and
incubated at room temperature for 30 min. The optical den-
sity (O.D.) at a wavelength of 492 nm was recorded. The
background O.D. was less than 0.05 (Fab, IgG). An O.D. of
less than 0.3 (Fab) or 0.6 (IgG), which were the mean plus
one standard deviation of a normal group respectively, was
considered HAMA negative. When the O.D. was more than
0.3 or 0.6, an absorption test was performed. In short, serum
was diluted in geometric progression with PBS containing
murine MoAbs, and serum was also diluted with PBS as
control. HAMA was determined in these aliquots by the
above assay. Absorption rate was calculated as:
{O.D. (control)-O.D. (absorption))/O.D. (control) x 100(%).
When the O.D. was more than 0.3 (Fab) or 0.6 (IgG) and
the absorption rate was more than 50%, the aliquot was
considered HAMA positive. The results are expressed as
dilution titers of the most diluted aliquots that showed
positive HAMA tests.
Size exclusion high performance liquid chromatography
(HPLC) analysis
One hundred jil of serum sample was incubated for 16 h at
4°C with 50 ng of radiolabelled MoAbs in a total volume of
400pl in 0.15 M PBS containing 0.25% BSA. They were
applied to HPLC system with a TSKgel G3000SW column
(7.5 mm x 60 cm) (Tosoh, Tokyo, Japan) equilibrated in
0.1 M phosphate buffer. Protein was detected at the absor-
bance of 280 nm. An outline detector Model 170 (Beckman
Instruments Inc., Berkley, CA, USA) was connected to
monitor the radioactivity of each fraction. The immune com-
plex formation was detected as radioactivity fraction of a
molecular weight larger than the injected material. A com-
puter program that analysed chromatographic curves was
used to determine the percentage of radioactivity found in
complexes. Inhibition studies were performed to ascertain
whether this immune complex formation could be blocked by
adding normal ICR or BALB/c murine serum or unlabelled
corresponding MoAbs. After patient sera (100 l), radio-
labelled MoAb (50 ng 501l-') and 250 tl of normal murine
serum or unlabelled MoAb (50fig) were mixed together in a
total volume of 400 gl, and incubated for 16 h, then similarly
analysed by HPLC.
Patients
HAMA positive sera were obtained from seven patients who
had received radiolabelled murine MoAbs (Table I). These
included three patients with colorectal cancer who received
42 mg of "'In-labelled ZCE-025 (Abdel-Nabi et al., 1987),
whose serum CEA levels were all within normal limits of
2.5 ngml-', two patients with malignant melanoma who
were injected with 20mg of 96.5 and/or 20 mg of ZME-018
(Koizumi et al., 1988), one pancreatic cancer patient who was
administered with 2 mg of '3'I-labelled F(ab')2 fragment of
MoAb mixture recognising CA19-9 and CEA (Chatal et al.,
1984), and one patient with acute myocardial infarction who
received 0.5 mg of "'In-labelled Fab fragment of anti-myosin
Ab RllDIO (Khaw et al., 1987). Serum samples were separ-
ated from peripheral blood obtained before and after in-
fusion with radiolabelled MoAbs and stored at - 20°C until
use. HAMA of these seven cases determined by ELISA were
all negative before MoAb administration but were positive at
2 to 4 weeks after infusion.
Results
Almost all radioactivity of radiolabelled MoAb when chrom-
atographed alone or after incubating with normal human
serum, remained associated with the IgG (Figure la) or Fab
(Figure lb) peak reflecting the molecular weight of the
injected material. With HAMA positive sera, examined using
five radiolabelled murine IgG; ZCE-025, 96.5, NL-1, SF-25
or Fab fragment of RI 1D10, the radioactivity was associated
with an entity having a higher molecular weight than original
IgG (Figure Ic) or Fab peaks, forming immune complexes
composed of HAMA-antibody. The percentage of immune
complex formation as determined by HPLC was significantly
correlated with HAMA titers determined by the ELISA assay
(Table I).
Table I Patient characteristics and determination of HAMA by ELISA and HPLC analysisa
% Complexformation by HPLC
Patient Age, sex Infused Ab HAMA titer ZCE-025 96.5 RJJDJO Fab NL-J c NL-1 SF-25 cSF-25
no. disease form/dose by ELISA PBS NMS PBS NMS PBS NMS PBS NMS PBS NMS PBS NMS PBS NMS
1. 61 Male ZCE-025 x 12,150b 100 10 88 4 87 0 100 4 13 12 100 19 11 12
colon ca. IgG/42 mg x 1,350c
2. 55 Female ZCE-025 Negativeb 80 18f 55 5 0 0 64 2 0 0 38 15 10 12
colon ca. IgG/42 mg x 450c
3. 55 Female ZCE-025 Negativeb 27 0 9 4 0 0 7 0 0 0 31 13 10 12
colon ca. IgG/42 mg x 150c
4. 58 Male IMACIS-1 x 1,350b 100 0 89 6 100 0 100 0 5 5 100 13 10 13
pancreas ca. F(ab')2/2 mg x 1,350c
5. 76 Male ZME-018, 96.5 x 5,120b 100 3 87 28 100 0 100 14 17 12 100 17 14 12
melanoma IgG/20mg each N.D.C
6. 65 Male ZME-018 x 2,560b 100 3 87 4 34 0 100 3 15 4 100 24 18 20
melanoma IgG/20 mg N.D.c
7. 78 Male RllDIO x 450b N.D. 54 6 24 0 84 5 7 7 N.D. N.D.
AMI Fab/0.5 mg N.D.c
Normal human serum 3.7 5.2d 3-8d Oe 3-9e 9 15e 13.5 ± 2.9d 9.5 ± 1.6d
aThe level ofcomplex formation was expressed as the percentage ofcounts found in complexes. PBS; phosphate buffered saline/bovine serum
albumin. NMS; normal murine serum. N.D.; notdone. AMI; acute myocardial infarction; bFab fragmentofRI lD1O as immobilised Ab;'nixture of
murine MoAbs (IgG) as immobilised Abs; dmean ± s.d. of eight healthy adults; 'range of three healthy adults; f0% after addition of unlabelled
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Figure 1 Size exclusion HPLC chromatograms of "'In-labelled
ZCE-025 (IgG) (a,c,d) and "'In-labelled Fab fragment of anti-
myosin antibody (b). Vertical axis shows arbitrary scale of
radioactivity. a,b, "'In-labelled IgG (a) and "'In-labelled Fab (b)
after incubation with normal human serum. c, "'In-labelled ZCE-
025 after incubation with HAMA positive serum (case 4), the
radioactivity was eluted in a higher molecular weight peak
(Vo;void volume) than the original IgG peak. d, "'In-labelled
ZCE-025 after incubation with HAMA positive serum (case 4)
and normal murine serum. Addition of normal murine serum
displaced almost all the radioactivity to the original IgG peak.
This immune complex formation could be inhibited by
incubating with excess normal murine serum and most
radioactivity was displaced to the parental IgG (Figure Id)
or Fab peak. In case 2 with colorectal cancer who had
previously received 42 mg of ZCE-025 Ab, and case 5 with
malignant melanoma who had previously received 20 mg of
96.5 Ab, 18% and 28% of the radioactivity was still assoc-
iated with the immune complexes, respectively, even after
incubation with excess normal ICR or BALB/c murine
serum. However, the immune complex formation could be
completely absorbed by incubating with 50pg of unlabelled
ZCE-025 Ab, but not by other anti-tumour MoAbs, indi-
cating the presence of anti-idiotype Ab in the serum of case
2. (Case 5 was not determined due to the lack of unlabelled
96.5 Ab).
Fab fragments of murine MoAbs and chimeric human/
mouse antibodies demonstrated different reactivities. Cases 2
and 3, who received whole IgG, failed to form immune
complexes with RlID0 Fab as determined by HPLC ana-
lysis and ELISA assay, whereas cases 4 and 7 who were
infused with F(ab')2 and Fab fragments, respectively, were
reactive with "'In-labelled Fab fragment as well as with all
whole IgGs examined. After incubating chimeric NL-1 and
SF-25 antibodies with HAMA positive serum, minimal for-
mation of the higher molecular weight species was detectable,
which was hard to displace by adding excess normal human
(data not shown) or normal murine sera (Figure 2). Similar
small immune complex formation was seen in normal human
serum (Table I).
Discussion
Murine MoAb infusion in humans should induce a HAMA
response, which may be a key obstacle to the repeated
infusion of MoAbs (Reynolds et al., 1989; Dillman, 1990).
To evaluate HAMA, we used ELISA and size exclusion
HPLC analysis and significant relation was observed between
titers assessed by the two methods. HPLC provides a simple
method to evaluate changes in molecular size as would occur
with the formation of radiolabelled MoAb and HAMA
(Reynolds et al., 1987). In our HPLC system, the 50 ng of
radiolabelled MoAbs in 100 lI of HAMA positive serum is




Figure 2 Size exclusion HPLC chromatograms of '251I-labelled
NL-1 and cNL-1 after incubation with HAMA positive serum
(case 5). a,b, 125I-labelled NL-1 showed a higher molecular weight
peak (a). Addition of normal murine serum displaced most of the
radioactivity to the original IgG peak, but some of the radioac-
tivity remained in the higher molecular weight peak (b). c,d,
'25I-labelled cNL-l formed a smaller peak than the original NL-1
(c), which was slightly absorbed after incubation with normal
murine serum (d).
equivalent to 1.5 mg of MoAbs in 3,000 ml of plasma
volume. If MoAbs exceed this quantity, the complex forma-
tion of MoAbs and HAMA decreases. Since more than
1.5 mg of MoAb is infused in most of the clinical
immunoscintigraphies, our HPLC assay estimates sufficiently
the degree of the in vivo complex formation. However, it is
difficult to distinguish anti-idiotypic antibodies from cir-
culating antigens by incubating sera with MoAbs and analys-
ing the complex formation using HPLC. Binding of "'In-
labelled ZCE-025 to the serum of case 2 with colorectal
cancer was not wholly blocked by excess normal murine
serum or by murine MoAbs, although excess unlabelled
ZCE-025 inhibited the binding completely. The serum CEA
concentrations in case 2 were within upper normal limits of
less than 2.5 ng ml-' (serum CEA levels exceeding
100 ng ml-' were detectable by our HPLC system, data not
shown), and a part of HAMA in this patient seemed to be
reactive with the idiotype of ZCE-025 antibody (Shawler et
al., 1985).
Fab or F(ab')2 fragments are expected to reduce the rate of
developing HAMA after the injection of murine Abs. Brown
et al. reported the absence of HAMA response in 663
patients who were given 0.5 mg of "'In-labelled anti-myosin
Fab fragments (Brown et al., 1988). However, in the multi-
center studies performed in Japan, five out of 406 (1.2%)
patients developed HAMA after a single infusion of anti-
myosin Fab, determined using a similar ELISA assay (Kawai
et al., 1990). A positive HAMA response to the IgG and Fab
was also found in case 7 with acute myocardial infarction
using HPLC analysis. The difference in the incidence of
HAMA in patients with heart diseases between the USA and
Japan remains to be explained.
Another approach, which should reduce HAMA But util-
ise murine MoAb is the generation of human/mouse chimeric
MoAbs (Morrison et al., 1984; Brown et al., 1987). Genetic
technology has made possible the exchange of the mouse
constant region domains with those of human, to fabricate
human/mouse chimeric antibodies, which retain the murine
variable region but otherwise are human (Nishimura et al.,
1987). By ligating the human heavy-chain enhancer element
to chimeric light- and heavy-chain genes, human/mouse
chimeric MoAbs were produced efficiently which reacted with
a common acute lymphocytic leukaemia antigen (CALLA).
Two human/mouse chimeric antibodies demonstrated little if
any, reactivity with seven HAMA positive sera.
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The sera of cases 4 and 7 obtained after the infusion of
F(ab')2 and Fab fragments, respectively, were reactive with
both murine IgG and Fab, but not with the human/mouse
chimeric monoclonal antibodies. It is very likely that the sera
of the two patients and three out of five patients who
received whole IgG and showed complex formation with
RIlD0 Fab, reacted with the CHI and/or CL regions of the
murine IgG. All seven HAMA positive sera bound to all
radiolabelled murine MoAbs (IgG) and five out of seven
patients were reactive with Fab of murine MoAb. In con-
trast, cNL-l or cSF-25 MoAbs were not reactive with these
HAMA positive sera. In the clinical studies using the human/
mouse chimeric MoAbs, the antibody responses of the
patients depend upon the infused chimeric MoAb, and the
immunogenic potential of the chimeric MoAbs ranges wide
(Meredith et al., 1991). The human/mouse chimeric MoAbs,
especially those with low immunogenicity, are useful for
repeated infusion of anti-tumour MoAbs in HAMA positive
patients. Meanwhile, excess normal murine serum did not
completely displace the binding of NL-1 or SF-25 MoAbs to
HAMA positive serum and up to 15 to 24% of radioactivity
was observed in a large molecular weight peak even after
incubating with HAMA negative normal human serum. NL-
1 recognises common acute lymphocytic leukaemia antigen
(CALLA), which is identical with neutral endopeptidase
(Letarte et al., 1988; Monod et al., 1989), and is clinically
employed as an important cell surface marker for the diag-
nosis of human acute lymphocytic leukaemia. However,
CALLA is not restricted to leukaemic cells and is also found
on a variety of normal tissues (Losa et al., 1986). Complexes
formed after adding normal murine serum or when incubated
with normal human serum are most likely due to the binding
of circulating antigens with radiolabelled MoAbs.
In summary, (1) HAMA of all seven patients formed
complexes with all four murine IgGs, but not with two
human/mouse chimeric antibodies, (2) five out of seven
patients showed reactivity with Rl11DIO Fab in their sera,
suggesting that they have HAMA recognising CHI or CL
region, (3) one patient seemed to have anti-idiotypic anti-
body. HAMA showed variety in reactivity with murine
MoAbs but human/mouse chimeric antibodies are promising
even in most patients who became HAMA positive after
repeated infusion with murine MoAbs.
The authors are grateful to Centocor and Toray Industries, Inc. for
the supply of SF-25 and cSF-25 antibodies.
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